141 related articles for article (PubMed ID: 21859882)
1. Toxicologic pathology in a multicultural world--India.
Schultze AE; Reddy VR; Donnelly KB; Berridge BR
Toxicol Pathol; 2011 Oct; 39(6):1003-9. PubMed ID: 21859882
[TBL] [Abstract][Full Text] [Related]
2. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
3. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
4. Herbal drug patenting in India: IP potential.
Sahoo N; Manchikanti P; Dey SH
J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
[TBL] [Abstract][Full Text] [Related]
5. Pharma industry in India.
Sundaram VM
Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810
[TBL] [Abstract][Full Text] [Related]
6. Emerging trends in contract research industry in India.
Drabu S; Gupta A; Bhadauria A
Contemp Clin Trials; 2010 Sep; 31(5):419-22. PubMed ID: 20609394
[TBL] [Abstract][Full Text] [Related]
7. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
9. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
10. India's growing clinical research sector: opportunity for global companies.
Varawalla N
IDrugs; 2007 Jun; 10(6):391-4. PubMed ID: 17642002
[TBL] [Abstract][Full Text] [Related]
11. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.
Melethil S
AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948
[TBL] [Abstract][Full Text] [Related]
12. The role of the toxicologic pathologist in the biopharmaceutical industry.
van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM
Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555
[TBL] [Abstract][Full Text] [Related]
13. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
Kettler HE; Modi R
Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
[TBL] [Abstract][Full Text] [Related]
14. Family pediatrics: report of the Task Force on the Family.
Schor EL;
Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
[TBL] [Abstract][Full Text] [Related]
15. Digital pathology in drug discovery and development: multisite integration.
Potts SJ
Drug Discov Today; 2009 Oct; 14(19-20):935-41. PubMed ID: 19596461
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. The impact of TRIPS on innovation and exports: a case study of the pharmaceutical industry in India.
Malhotra P
Indian J Med Ethics; 2008; 5(2):61-5. PubMed ID: 18624153
[TBL] [Abstract][Full Text] [Related]
18. Need and opportunities for health management education in India.
Sharma K; Zodpey S
Indian J Public Health; 2010; 54(2):84-91. PubMed ID: 21119241
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials and contract research organizations in India.
Mukherjee S
Clin Lab Med; 2012 Jun; 32(2):315-20. PubMed ID: 22727008
[TBL] [Abstract][Full Text] [Related]
20. [Biomarkers: "Found in translation"].
Lockhart BP; Walther B
Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
